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A current goal of vaccine development against human immunodeficiency virus (HIV) is to develop a strategy that stimulates long-lasting
memory T-cell responses, and provides immediate cytotoxicity in response to viral challenge. We demonstrate that the viral antiapoptotic molecule
M11L promotes cellular immune responses to the HIV envelope protein. Coexpression of M11L in vitro inhibits gp140-mediated apoptosis and
increases gp140 expression levels. Mice primed with M11L-pHERO DNA, followed by vCP205 boosting, exhibit significantly greater HIV-
specific T-cell responses. Moreover, M11L synergizes with CpG motifs to augment anti-HIV responses and stimulates robust expansion of central
memory and effector memory CD8+ T-cells. Inclusion of M11L in a DNA vector increases the magnitude of T-cell responses, and promotes the
generation of memory T-cells that provide rapid-responding CTL responses. This vaccine strategy may facilitate the generation of an efficacious
vaccine for HIV, and other chronic diseases that require enhanced cell-mediated immunity, including HCV and metastatic cancer.
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The HIV pandemic and ensuing AIDS crisis is one of the
greatest contemporary health challenges and will probably be
controlled only when a safe and effective vaccine is developed.
HIV presents unique obstacles to vaccine design due to its
sophisticated immune evasion strategies and ability to rapidly
generate genetic variants, thus making the generation of an HIV
vaccine a formidable challenge. There is ample evidence that
vaccine-induced cell-mediated immune responses are requisite
for controlling a variety of chronic infectious diseases, including
HIV. Hence, a major focus of HIV vaccine design is to induce⁎ Corresponding author. Room 212, Robarts Research Institute, 100 Perth
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doi:10.1016/j.virol.2008.01.011enhanced cellular immune responses, particularly cytotoxic T
lymphocyte (CTL) activity. Currently, a promising HIV vaccine
strategy is a consecutive immunization regimen wherein DNA
expression vector priming is followed by boosting with
recombinant live viral vectors. This approach generates T-cell
immune responses against HIV in primates (Amara et al., 2001;
Dale et al., 2004; Shiver et al., 2002; Wee et al., 2002) and in
humans (McConkey et al., 2003; Mwau et al., 2004). However,
the efficacy and potency of DNA vector vaccines remain sub-
optimal. A number of strategies have been aggressively pursued
to improve the immunogenicity of plasmid DNA vectors,
including formulation with liposomes or polymers to retard
DNA degradation (Alpar et al., 2005; Greenland et al., 2005),
development of novel delivery technologies to increase in vivo
transfection efficiency (Otten et al., 2006), incorporation of
unmethylated CpGmotifs, and co-administration with cytokines
or co-stimulatory molecules to augment immune function
(Barouch et al., 2000; Kutzler et al., 2005; Kim et al., 1997a,
1998, 1997b). Although these strategies increase the number of
49J. Su et al. / Virology 375 (2008) 48–58Ag-specific effector T cells, they do not efficiently augment
long-lived memory cells that provide durable and enhanced
reactivity when Ag re-appears.
Recently, some interesting but controversial approaches have
been evaluated to enhance DNA vaccine immunogenicity by
manipulation of cellular apoptotic regulators in Ag-expressing
and presenting cells, including the pro-apoptotic molecules
caspase 2 and 3 (Sasaki et al., 2001), and anti-apoptotic protein
Bcl-xL (Kim et al., 2004, 2003). However, these apoptotic
modulators are subject to normal cellular regulatory mechan-
isms and therefore the efficacy of such approaches may vary
depending on the type and/or state of differentiation of the cell
they are expressed in, the choice of Ag, or the particularFig. 1. Construction of pHERO vaccine vectors and effects of M11L on expression
of vaccine Ag gp140 in vitro. (A). The HIV DNAvaccine construct pHERO-CpG-
M11L-gp140. (B). Increased expression of HIV gp140 in cells transfected with the
M11L-coexpressing pHERO construct. Mouse L cells were transfected with
pHERO-gp140 or pHERO-M11L-gp140. Expression of gp140 in cell lysates was
detected by immunoblotting using anti-serum from an HIV+ subject. Detection of
β-actin was used as a sample loading control. (C). The intensities of the gp140 bands
were analyzed by densitometry. The OD values of the gp140 bands were normalized
to the correspondingβ-actin bands.Numbers depicted aremeans±standard deviation
(SD) from three independent experiments. * indicates significant differences.
Fig. 2. Transfection with pHERO-M11L constructs provides resistance to HIV
gp140-mediated apoptosis. Mouse L cells were transfected with pHERO vectors
using lipofectamine and samples were harvested at 24 h post-transfection. Lane 1,
cells transfected with lipofectamine alone; lane 2, pHERO-gp140; lane 3, pHERO-
M11L-gp140; lane 4, pHERO-CpG-gp140; lane 5, pHERO-CpG-M11L-gp140;
lane 6, the empty pHERO vector. (A). Co-expression of M11L renders cells
resistant to gp140-mediated apoptosis. Caspase activity was measured in cell
lysates and the fold increase calculated relative to non-transfected cells. Data
presented are means±SD from three independent experiments. * indicates there is
no significant difference among these samples. (B). The protein production of HIV
gp140 and M11L in the transfected cells was confirmed by immunoblotting.
Detection of β-actin was used as sample loading controls.immunization vector. Here we demonstrate for the first time that
a viral anti-apoptotic molecule, M11L, enhances Ag-specific
cell-mediated immunity when co-expressed with a DNA
vaccine vector. M11L is a structural homolog of Bcl-2 (Douglas
et al., 2007) encoded by the rabbit poxvirus, myxoma virus. In
previous studies we have found that M11L blocks apoptosis by
binding to key mitochondria-associated apoptotic inducers
including the mitochondrial peripheral benzodiazepine receptor
(PBR) (Everett et al., 2002), Bak (Wang et al., 2004) and
activated Bax (Su et al., 2006). It has also been shown that Ag
presenting cells transfected with BAK/BAX siRNA are able to
elicit stronger immune responses (Kang et al., 2007; Peng et al.,
2005). Hence, we expected that the inhibition of Bak and Bax
by M11L would function in a similar manner. In this study, we
have employed the DNA vector, pHERO, which contains the
EBV oriP and EBNA-1 gene endowing the vector with
improved stability and increased persistence (Marsh et al.,
2000). Thus, M11L expression combined with the enhanced
stability of pHERO should increase the amount and duration of
gp140 expression by extending cell survival and reducing
apoptosis associated with gp140 over expression (Gougeon and
Montagnier, 1993; Lu et al., 1994). We demonstrate that
immunization with pHERO-M11L-based vaccines stimulate
strong and persistent immune responses. Specifically, we have
found that M11L synergizes with CpG motifs in a prime-boost
regimen to significantly enhance vaccine-elicited cell-mediated
Table 1
Immunization groups
Cardiotoxin Prime ALVAC vCP205
Group 1 Yes pHERO-CpG-M11L 2×107 pfu
Group 2 Yes pHERO-gp140 2×107 pfu
Group 3 Yes pHERO-CpG-gp140 2×107 pfu
Group 4 Yes pHERO-M11L-gp140 2×107 pfu
Group 5 Yes pHERO-CpG-M11L-gp140 2×107 pfu
50 J. Su et al. / Virology 375 (2008) 48–58effector activities and generation of HIV-specific CD8+ memory
T cells.
Results
Construction of pHERO vaccines and effects of M11L on
Ag-expressing cells in vitro
The gene encoding the vaccine Ag HIV gp140 was inserted
into pHERO under the control of the CMV promoter (Fig. 1A).
The fragment encoding M11L was inserted downstream of the
hEF1α promoter to avoid interference with the CMV promoter.
A fragment containing repeated murine CpG motifs obtained
from the plasmid pBISIA-CpG (Pontarollo et al., 2002) was
inserted into pHERO.Fig. 3. pHERO-M11L vectors stimulate strong cellular immune responses inmice
after DNA priming followed by boosting with ALVAC vCP205. HIV-specific
Tcell responses (number of IFNγ spot forming cells (SFC)/106 splenocytes) were
assayed by ELISPOT and calculated by subtracting the background (medium-
stimulated wells). Data presented are means±standard error means (SEM, n=12)
from two independent experiments. (A). Vaccine-elicited HIV-specific IFNγ
ELISPOT responses following re-stimulation with the HIV peptide pool. (B).
Vaccine-elicited HIV-specific IFNγ ELISPOT responses following re-stimulation
with CLP97 which represents a known immunodominant CTL epitope in HIV
envelope V3 loop recognized by BALB/c mice.Mouse L cells were transfected with pHERO vectors and then
harvested at multiple time points (0–120 h). Expression of gp140
was assessed by Western blotting (Fig. 1B). Densitometric
analysis reveals that co-expression ofM11L induces significantly
larger amounts of gp140 by 24 h post-transfection (Fig. 1C). In
the presence of M11L (pHERO-M11L-gp140), maximal gp140
expressionwas observed at 96 h post-transfection (592OD/mm2)
whereas transfection with gp140 alone (pHERO-gp140) yielded
40% less protein (344 OD/mm2) and reached a plateau by 48 h.
Similarly, transfection with pHERO-CpG-M11L-gp140 pro-
duced significantly greater amounts of gp140 compared with
pHERO-CpG-gp140 (data not shown).
Transfection efficiency was monitored by co-transfection of
pGL3 expressing luciferase and confirmed that the above differ-
ences did not result from variation in transfection efficiency. In
addition, transfection of human HEK293 with pHERO vectors
led to gp140 expression profiles similar to those observed in
mouse L cells (data not shown).
To test if M11L provides protection from apoptosis induced
by the over expression of soluble gp140, L cells were harvestedFig. 4. Mice exhibit strong cytotoxic killing activity following vaccination with
M11L-pHERO vectors followed by boosting with vCP205. Target cells p815
were pre-labeled with the cellular dye DDAO-SE and loaded with HIV peptides.
Detection of cleaved caspase 3 in target cells indicates cytotoxic killing. (A). A
representative example showing detection of activated caspase 3, in DDAO-SE-
labeled cells in an unimmunized mouse and one immunized with pHERO-CpG-
M11L-gp140. The background cytotoxic killing (stimulated with medium alone)
is usually below 1%. (B). Vaccine-elicited HIV-specific cytotoxic killing activity
detected in mice that received a prime-boost vaccination. Data presented are
means±SEM (n=12) from two independent experiments.
Fig. 5. A single primary immunization with M11L-pHERO vectors stimulates
cellular immune responses indicating improved priming responses in vivo.
(A). Vaccine-primed HIV-specific cellular immune responses stimulated with the
HIV peptide pool, measured by the number of IFNγ spot forming cells (SFC/106
splenocytes) and calculated by subtracting the background. Data presented are
means±SEM (n=12) from two independent experiments. (B). Mice primed with
M11L-pHERO vectors exhibit improved cytotoxic killing activity. Detection of
cleaved caspase 3 in the target cells by flow cytometry indicates cytotoxic killing.
Data presented are means±SEM (n=12) from two independent experiments.
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suring caspase activity (including caspase 3, 7 and 10). Treating
L cells with transfection agent does not induce significant
apoptosis in L cells (Fig. 2a, column 1). However, tranfection
agent plus empty pHERO vector induces a 15 fold increase in
caspase activity in L cells and this level serves as the baseline
against which the different pHERO gp140 constructs were
compared against. Over expression of HIV gp140 by transfection
with pHERO-gp140 or pHERO-CpG-gp140 increased caspase
activity a further 15 or 7 fold respectively (Fig. 2A, columns 2
and 4). In contrast, in the presence of M11L (pHERO-M11L-
gp140 and pHERO-CpG-M11L-gp140, Fig. 2A, columns 3 and 5
respectively) caspase activity was maintained at the baseline level
observed following transfection with the empty pHERO vector.
The expression of gp140 and M11L in transfected cells was
confirmed by Western blotting (Fig. 2B). These results demon-
strate that co-expression of M11L by the pHERO vectors confers
resistance to gp140-mediated apoptosis and leads to increased and
prolonged Ag expression in DNA-transfected cells.
Vaccination withM11L-pHERO vectors in a prime-boost regimen
enhances the generation of Ag-specific cellular immune responses
As transfection with M11L increased vaccine Ag expression
and resistance to apoptosis, we next determined if pHERO-
M11L vectors are more immunogenic in vivo. Mice were
primed with pHERO vectors and boosted with ALVAC vCP205
three weeks later (Table 1). Spleen cells were collected 14 days
after boosting and re-stimulated ex vivo with a pool of HIV
envelope peptides, or the peptide CLP97 (a known HIV CTL
epitope). HIV-specific responses detected by the IFN-γ ELI-
SPOT assay in response to the peptide pool (50 ng/ml per
peptide) are shown in Fig. 3A. The number of IFN-γ secreting
cells detected in animals primed with pHERO-M11L-gp140
(141 SFC/106 cells) was three-fold greater compared with
pHERO-gp140 (45 SFC/106 cells, pb0.01, supplementary
Table S1). Immunization with pHERO-CpG-gp140 also
potently induced IFN-γ secreting cells (183 SFC/106 cells).
Since CpG motifs are a commonly used adjuvant in DNA
vaccines, we determined if they synergize with M11L to
enhance immunogenicity. Immunization with pHERO-CpG-
M11L-gp140 elicited the strongest stimulation with a more than
nine fold increase in IFN-γ-secreting cells (415 SFC/106 cells)
compared to pHERO-gp140. This response was significantly
greater compared with all other pHERO vectors (pb0.01). The
animals administered the sham construct pHERO-CpG-M11L
followed by ALVAC boosting exhibited non-detectable to very
low responses. This indicates that in the absence of priming by a
gp140-expressing pHERO vector, ALVAC immunization at the
dose used in this study does not stimulate detectable HIV-
specific immune responses.
We also examined immune responses toward CLP97
(Fig. 3B). Analysis of animals primed with gp140-expressing
constructs revealed significantly increased numbers of IFN-γ
SFC/106 cells, 383, 683, 643 and 1430 for pHERO-gp140,
pHERO-CpG-gp140, pHERO-M11L-gp140 and pHERO-
CpG-M11L-gp140, respectively. These responses were HIVgp140-specific as spleen cells produced zero to five IFNγ
SFC/106 cells in response to medium, or the irrelevant peptide
HA-2 (a known influenza CTL epitope). These experiments
were repeated in a separate group of identically immunized
mice. However, the spleen cells were first enriched for CD8+
or CD4+ T cells by negative selection using immunomagnetic
beads to deplete either CD4+ or CD8+ T cells, respectively.
The number of IFN-γ SFC/106 cells responding to the CLP97
peptide in CD4+-depleted cultures was, as expected, signifi-
cantly greater (80±45 and 1139±425 SFC/106 cells for
pHERO-gp140 and pHERO-CpG-M11L-gp140, respectively;
n=8 for both groups) compared to that observed in CD8+-
depleted cultures (13±11 and 34±11 SFC/106 cells pHERO-
gp140 and pHERO-CpG-M11L-gp140, respectively; n=8 for
both groups). Taken together, these data demonstrate that co-
expression of M11L in pHERO vectors enhances vaccine
immunogenicity in vivo. In addition, M11L synergizes with
CpG motifs and stimulates greater numbers of HIV-specific
IFN-γ secreting CD8+ T cells.
In addition, we compared the immunogenicity of pHERO
with a conventional DNA vaccine vector, pBISIA-CpG-gp140
(supplementary Fig. S1 and Table S1). pBISIA-CpG-gp140
priming yielded 60% fewer IFN-γ secreting cells (73 SFC/106
52 J. Su et al. / Virology 375 (2008) 48–58cells) in response to the peptide pool compared to that achieved
with pHERO-CpG-gp140. Similar results were obtained with
CLP97 (342 vs 683 SFC/106 cells for pBISIA-CpG gp140 andpHERO-CpG-gp140, respectively). These findings demonstrate
the potential advantage of using pHERO as a DNA vaccine
platform.
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killing activity
To determine if vaccine-elicited T cells possess the critical
cytotoxic killing function, spleen cells from prime-boost
immunized mice were re-stimulated with HIV peptides and
then co-cultured with p815 target cells pre-labeled with DDAO-
SE and loaded with HIV peptides. Cytotoxic activity was
detected by the presence of activated caspase 3 in the target cells
(Fig. 4A). Spleen cells from mice immunized with gp140-
expressing vectors all showed significantly greater killing
activity compared with the sham group (0.54% killing; pb0.01,
Fig. 4B and Table S1). Killing activity was approximately
equivalent in animals primed with pHERO-M11L-gp140
(10.26%) or pHERO-CpG-gp140 (11.56%). The presence of
M11L, or CpG, in the vaccine vector enhanced killing activity
by more than two fold compared to pHERO-gp140 (4.34%).
Consistent with ELISPOT results, priming with the combina-
tion vector pHERO-CpG-M11L-gp140 induced the greatest
cytotoxic activity (30.00%), nearly a seven-fold increase com-
pared to pHERO-gp140. Furthermore, as in the ELISPOT
assays, pHERO-CpG-gp140 was significantly better than
pBISIA-CpG-gp140 (11.56% vs 3.90%, supplementary Fig.
S1C and Table S1). These results confirm that CpG and M11L
can synergistically augment Ag-specific cytotoxic killing.
A. single administration of M11L-pHERO vaccines elicits
cellular immune responses
To further dissect the role of M11L in promoting cellular
immune responses, we examined the immunogenicity of pHERO
during the priming phase. Mice were primed with pHERO and
7 days later spleen cells were analyzed using IFNγ ELISPOT
(Fig. 5A) and cytotoxic killing (Fig. 5B) assays. Similar to the
prime-boost regimen, both pHERO-CpG-gp140 (30 SFC/106
cells) and pHERO-M11L-gp140 (39 SFC/106 cells) stimulated
more SFC than sham (1 SFC/106 cells), or pHERO-gp140
(5 SFC/106 cells), in response to the HIV peptides (Fig. 5A). A
single administration of pHERO-CpG-M11L-gp140 induced the
strongest IFNγ responses with 61 SFC/106 cells, which was
significantly greater than sham, or pHERO-gp140 (pb0.01,
Table S2). Indeed the induction of IFNγ-producing cells by a
single administration of pHERO-CpG-M11L-gp140 was equiva-
lent to immunization with pHERO-gp140 followed by ALVAC
boosting (45 SFC/106 cells, Fig. 3). A similar trend was observed
toward CLP97 (Fig. S2). In parallel, we conducted cytotoxic
killing assays (Fig. 5B) and found that animals primedwith sham,
or pHERO-gp140, exhibited little cytotoxic activity (0.85% or
1.20%, respectively). Priming with either pHERO-CpG-gp140
(2.27%), or pHERO-M11L-gp140 (2.31%), led to a small butFig. 6. Efficient generation of HIV-specific CD8+ central and effector memory T cell
prime-boost vaccinated mice were collected four weeks after the boost, and the phe
example of the phenotypic analysis performed on an un-immunized mouse and
(A) Lymphocytes were selected using forward and side scatter parameters. (B) N
(C–D) Subsequently, the HIV-specific CD8+ T cells were distinguished by expressi
CLP97-tetramer+CD62L+ and effector and/or effector memory T cells as CLP97-tetra
generated HIV-specific CD8+ central memory, and effector/effector memory populatsignificantly greater cytotoxic activity (pb0.01, Table S2).
Cytotoxic activity primed with pHERO-CpG-M11L-gp140 was
the greatest (4.32%) and significantly higher compared with
all the other pHERO vectors (pb0.01). Thus, the cytotoxicity
assays are in good agreement with the IFNγ ELISPOT data.
Taken together, these findings suggest that M11L improves
overall vaccine immunogenicity during the priming phase which,
in turn, augments the boosting phase. The addition of CpG to the
M11L-pHEROvector further enhances vaccine immunogenicity.
HIV-Env specific CD8+ central and effector memory T cells
following prime-boost vaccination
To assess the enduring functional capacity of vaccine-elicited
HIV-specific CD8+ Tcells, we examined the phenotype of CD8+
Tcells from prime-boost vaccinated animals four weeks after the
ALVAC boost. HIV-specific T cells were identified as
CD8+CD44+ and CLP97-tetramer+ (Fig. 6). As exemplified
by using NYVAC immunized mice as a positive control we were
able to use CD62L expression (Seaman et al., 2004), to further
distinguish HIV-specific CD8+ T cells as central memory cells
(CD62Lhigh), and effector and/or effector memory cells
(CD62L−/CD62Llow) (Fig. 6A–D). As shown in Fig. 6E–F,
animals received sham, or pHERO-gp140 prime followed by
ALVAC boost demonstrated background numbers of HIV-
tetramer+CD8+ central memory (1.09% or 1.49%, respectively)
and effector/effector memory cells T cells (0.47% or 0.63%,
respectively). Importantly, mice primed with pHERO-CpG-
M11L-gp140 showed a significantly greater expansion of both
central memory (6.48%) and effector/effector memory (4.15%)
HIV-tetramer+CD8+ T cells compared with all the other vaccine
groups (pb0.01, Table S3). The total number of lymphocytes
isolated from mice was similar among the vaccine groups (data
not shown). Combined, these findings demonstrate that the
combination ofM11L and CpG in a DNAvaccine leads to potent
immunization, including expansion of long-lived CD8+ memory
T cells, without grossly perturbing immune homeostasis.
Discussion
Accumulating evidence has shown that cellular immune
responses play a critical role in the control of persisting viruses
including HIV, EBV, CMV, HBV and HCV. Many studies have
correlated CTL activity with HIV clearance during acute
infection (Koup et al., 1994; Safrit et al., 1994), with delayed
onset of overt disease (Greenough et al., 1997; Rinaldo et al.,
1995), and possibly with protection in exposed, uninfected
individuals (Rowland-Jones et al., 1993, 1995). It is proposed
that several properties in a vaccine response are likely required
for obtaining a protective HIV-specific T-cell response. Theses after DNA prime-ALVAC boost in mice. Draining popliteal lymph nodes from
notype of the HIV-specific CD8+ T cells was analyzed by flow cytometry. An
one immunized only with NYVAC at three days post immunization (A–D).
aïve CD8+ lymphocytes were excluded by gating on the CD8+CD44+ cells.
on of CD62L and labeling with the CLP-97 tetramer: central memory T cells as
mer+CD62L− cells, respectively. (E–F) DNA prime-ALVAC boost vaccination-
ions from the vaccinated animals. Numbers depicted are means±SD.
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and magnitude, T cells with multiple effector functions, and the
induction of memory T cells capable of responding with the
correct differentiation pattern and preferential recognition of
conserved epitopes in HIV antigens. Currently no vaccine
candidate can fulfill these criteria and thus new strategies are
needed to improve vaccine efficacy.
We have demonstrated a new vaccination strategy that may
contribute to the successful development of an HIV vaccine and
includes three key components. First, we have included the viral
anti-apoptotic molecule M11L to promote cell survival and
persistent Ag expression. It is known that the HIV envelope
protein induces apoptosis which may limit the efficiency of Ag
presentation, and hence the vaccine-elicited immune response
(Castedo et al., 2001; Perfettini et al., 2005). The presence of
M11L clearly inhibited gp140-mediated apoptosis, and led to
persistently strong protein expression in vitro. We anticipate that a
similar prolonged cell survival and increased gp140 expression
profile occurs in vivo following i.m. immunization, which is
consistent with the enhanced immunogenicity of the M11L-
pHERO vaccines. Although the current study did not seek to
identify the cell population(s) that preferentially takes up theDNA
vaccine, it is likely these include myocytes and professional APC,
such asDC andmonocyte/macrophageswhich are attracted by the
cardiotoxin-induced inflammation at the injection site. Persistent,
stable expression of Ag encoded by pHERO-transfected APC
would facilitate the direct priming of MHC class I responses. In
this regard, it is important to note that our recombinant HIV gp140
can also be secreted, due to a truncation in the transmembrane
domain and the cytoplasmic tail (Hallenberger et al., 1993; Zhang
et al., 2001). Thus, increased secretion of gp140 by transfected
myocytes, and its subsequent up-take by professionalAPC,would
enhance MHC class I responses through cross-presentation, as
well as, enable presentation via MHC class II. In addition, Ag-
expressing and presenting cells may benefit from increased in
vivo persistence due to M11L-mediated protection from vaccine-
primedCTLs. It is likely that some or all of thesemechanisms play
a role in the priming of the anti-gp140 cellular responses that lead
to the enhanced effector functions and expansion of long-lived
central memory CD8+ T cells we observed.
Second, M11L synergizes with CpG motifs to further en-
hance DNAvaccine immunogenicity. The presence of increased
Ag-specific IFN-γ producing cells and functional cytotoxic
activities at seven days after priming with a single administration
of pHERO-CpG-M11L-gp140 indicates that the combined pro-
survival and pro-inflammatory mechanisms enhance T cell
responses. This distinct priming efficiency establishes a steady
foundation for recalled immune responses and thus very likely
accounts for the significant differences observed in T cell
responses after ALVAC boosting. This vaccine system elicits
robust Ag-specific cellular immune responses with respect to
two critical effector functions, IFN-γ secretion and cytotoxic
killing. In addition, it establishes an Ag-specific memory com-
posed of an operationally preferred T cell phenotype, a signif-
icantly increased combination of both central memory and
effector memory T cells, as detected in mice four weeks after
boosting. These two pools of memory T cells are criticalcomponents for a long-lasting and rapid memory response to an
intracellular pathogen (Williams and Bevan, 2007). Generally,
the long-lived central memory cells reside in lymphoid organs,
lack immediate lytic function and need several days to reactivate
and proliferate upon Ag reoccurrence. In contrast, the relatively
short-lived effector memory cells reside in non-lymphoid
tissues, possess immediate cytolytic responses following Ag
encounter but lack proliferative capacity (Weninger et al., 2002).
In our experiments, CD8+ Tcells were assessed four weeks after
the ALVAC boost, by which time the effector T cell population
should have contracted. However, we believe that the presence
of M11L leads to prolonged presentation of Ag which may
maintain enhanced numbers of effector T cells, in addition to
establishing greater numbers of effector memory T cells. Our
finding that expansion of central memory and effector, and/or
effector memory T cells was generated by pHERO-CpG-M11L-
gp140 is potentially a significant improvement in HIV vaccine
design. This vaccine elicits effector and/or effector memory T
cells that can provide immediate cytolytic activity against an
invading virus, until such time that the central memory T cells
can be reactivated to provide a long-term source of additional
effector T cells against the pathogen.
Lastly, the pHERO vector has the advantage of increased
stability compared to conventional plasmid DNA vectors. Our
previous studies have shown that the enhanced stability of
pHERO vectors led to prolonged Interleukin (Cameron et al.,
2000), or chemokine (Meagher et al., 2006) protein expression
following biolistic delivery in vivo. Comparing the immuno-
genicity of pHERO vectors with the conventional plasmid
pBISIA-CpG revealed that pHERO-CpGgp140 (and also
pHERO-M11L-gp140 and pHERO-gp140) stimulated signifi-
cantly greater responses compared with pBISIA-CpG-gp140.
In summary, the vaccine vector platform pHERO-CpG-
M11L elicits improved T cell responses to the encoded Ag HIV
gp140 in a mouse immunogenicity model. The robust T cell
responses elicited by this unique system, along with the
increased expansion of both central memory and effector and/
or effector memory CD8+ T cells, indicates that this strategy
may be of value in vaccine designs targeting HIV and other
chronically persisting pathogens, or cancer.
Materials and methods
Construction of plasmid DNA
pHERO contains the EBV genes of oriP and EBNA-1 to
facilitate stable episomal maintenance of the vector following
gene transfer (Marsh et al., 2000). HIV Env gp140 was
generated by combining the codon-optimized, Rev-independent
HIV BX08 Env sequence coding for gp120 (received from
Sanofi-Aventis, Toronto, Canada) and the first 480nt of gp41
coding sequence from an R5 phenotype HIV primary isolate
91US006.10 (received from NIH AIDS Research and Reference
Reagent Program, USA). HIV gp140 was inserted first into the
cloning vector pWRG (Hota-Mitchell et al., 1997), in which
gp140 is located downstream of the CMV immediate early
promoter and the human β-globin intron A, and upstream of the
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fragment containing the CMV promoter, intron A, gp140 and
polyA was inserted into pHERO at the SalI site (Fig. 1A). The
fragment containing M11L from myxoma virus was inserted
into pHERO between the BamHI and XbaI sites under the
control of the hEF1α promoter. A fragment containing repeated
murine CpG motifs was obtained from the plasmid pBISIA-
CpG (Pontarollo et al., 2002) (received from Dr. Lorne Babiuk,
VIDO, Saskatoon, Sasakatchewan, Canada) and inserted into
pHERO at the BglII site. The HIV gp140 fragment was also
inserted into pBISIA-CpG plasmid for comparative purposes.
All the inserted sequences were confirmed by DNA sequencing.
Plasmid DNAwas prepared using Endo-Free plasmid maxi kits
(QIAGEN, Valencia, CA) and diluted in PBS for immunization
in mice. It should be noted that the BXO8 gp120 sequence is
different from the HIVMN gp120 sequence present in the
ALVAC vcp205 vector used in the boost although both contain
nearly identical V3 loop CTL epitope sequences.
Transfection and Western blotting
Mouse fibroblast L cells and human embryonic kidney cells
HEK293were maintained in DMEM containing 10% (v/v) FBS.
Transfection was performed with 10 µg of plasmid DNA using
Lipofectamine 2000 according to the manufacturer's instruction
(Invitrogen Carlsbad, CA). Transfected cells were collected at
multiple time points (0–120 h) and cell lysates were prepared as
described previously (Su et al., 2006). Soluble proteins (20 μg)
were resolved on a 7.5% denaturing SDS-PAGE and transferred
onto a nitrocellulose membrane. Immunolabelling of gp140
protein was carried out using a human serum sample from an
HIV+ subject followed by the goat anti-human-HRP antibody
(Ab) (Jackson Immunoresearch, West Grove, PA). Immunor-
eactive bands were visualized using the SuperSignal West Pico
chemiluminescent substrate (Pierce Biotechnology, Rockford,
IL). Membranes were subsequently stripped and re-probed with
anti-β-actin Ab (Sigma-Aldrich Inc., St. Louis, MI) to confirm
the loading of the proteins. Expression of M11L in the
transfected cells was detected by Western blotting using a rabbit
polyclonal Ab against M11L followed by goat anti-rabbit-HRP
Ab (Jackson Immunoresearch, Westgrove PA) as described
previously (Su et al., 2006). The intensities of the Western
blotting bands were determined by a Molecular Imager GS-800
Calibrated Densitometer (BioRad Laboratories, Hercules, CA)
and calculated using Quality One software (BioRad Labora-
tories). The intensities of the gp140 bands were normalized
according to that of the corresponding β-actin bands. In some
experiments, transfection efficiency was monitored by co-
transfecting the pGL3 plasmid encoding the firefly luciferase
(Promega Corporation, Madison, WI) and the expression of
luciferase in the transfected cells was measured by the
Luciferase Assay System (Promega Corporation).
Caspase activity assay
Transfected cells were harvested after 24 h and the level of
apoptosis in the cells was measured using the CasPASEapoptosis assay kit according to the manufacturer's instruction
(G-Biosciences/Genotech, St. Louis, MO). Briefly, cells were
lysed with 200 µl CasPASE lysis buffer by passing the cell
suspension 10–15 times through a 25-gauge needle. The cell
lysate was cleared by centrifugation at 15,000 ×g for 30 min at
4 °C. Subsequently, 50 µl of cell lysate was mixed with 50 µl of
2× CasPASE assay buffer in a 96-well plate. After 5 µl of AFC-
conjugated substrate was added, the plate was incubated at
37 °C for 40 min, and duplicate samples were read at 527 nm
wavelength using Fluoroscan Acent FL (Thermo Labsystems,
Helsinki, Finland). The OD values from the DNA-transfected
cells were compared with untransfected cells and the fold in-
crease in caspase activity was calculated.
Animals, immunization and sample collection
Six- to eight-week-old male BALB/c (H-2d) mice were
obtained from Charles River Laboratories (Wilmington, MA)
and were cared for under protocols approved by the University
of Western Ontario Animal Use Sub-committee. Six–eight mice
per group were used in i.m. immunizations consisting of a prime
with a DNA vector followed by boosting with a live recom-
binant canarypox vaccine vector, ALVAC vCP205 (Fang et al.,
1999) (received from Sanofi-Aventis, Toronto, Canada). Five
days before DNA immunization, mice were given 7 µg of snake
venom cardiotoxin (Sigma-Aldrich Inc.) in 50 µl by i.m. in-
jection into the left hind leg tibialis anterior muscle (Davis et al.,
1997).
Then, 50 µg of the endotoxin-free pHERO DNA in a volume
of 50 µl was given by i.m. injection into the same area of the left
hind leg. Three weeks after the DNA prime, 2×107 pfu of
ALVAC vCP205 in a volume of 50 µl was given by i.m.
injection into the same area of the left hind leg. Two weeks after
the ALVAC boost, animals were sacrificed and spleens and
lymph nodes were collected for analysis of immune responses
to HIV gp140. Some of the animals were sacrificed four weeks
after boosting to analyze memory immune responses. In certain
experiments, mice were immunized with plasmid DNA alone
then sacrificed seven days after vaccination to analyze the primary
responses. Cardiotoxin-treated, but non-immunized, mice were
used as negative controls in all the assays.
IFN-γ ELISPOT assay
Mouse spleens were passed through 70 µm cell strainers.
After RBC lysis with ACK lysing buffer (Cambrex Bio Science,
Walkersville, MD), spleen cells were resuspended in RPMI
1640 containing 10% FBS and 6 U/ml rIL-2. Where needed
CD8+ or CD4+ T cells were enriched by depleting CD4+ or
CD8+ T cells respectively with the appropriate immunomag-
netic beads according to the manufacturer's protocol (Stem Cell
Technologies, Vancouver, BC). A set of 212 peptides of 15-mer,
with 11 aa overlaps, derived from HIVMN envelope protein
gp160, were obtained from the NIH AIDS Research and
Reference Reagent Program. All peptides were dissolved
according to the instruction of the supplier then pooled for
immunological assays. A peptide, CLP97, which corresponded
56 J. Su et al. / Virology 375 (2008) 48–58to the sequence of V3 loop of HIV IIIB gp120, contains a
known immunodominant CTL epitope (also referred to as p18
peptide RGPGRAFVTI) restricted by the mouse MHC class I
allele H-2Dd (Doe et al., 1994; Bergmann et al., 1993) (received
from Sanofi-Aventis, Toronto, Canada). Both the vaccine Ag
gp140 encoded by the pHERO vectors and the envelope protein
encoded by ALVAC vCP205 express this particular immuno-
dominant CTL epitope in their V3 loops. A control peptide,
HA2, which corresponds to the sequence IYSTVASSLVL from
the influenza virus hemagglutinin protein, is a known CTL
epitope restricted by the mouse MHC class I allele H-2Kd
(Kuwano et al., 1988; Tamura et al., 1998) (received from
Sanofi-Aventis, Toronto, Canada). ELISPOT assays were
performed as previously described (Su et al., 2005) using the
mouse IFN-γ ELISPOT kit (BD Biosciences, San Jose, CA). A
portion of the unfractionated spleen cells (2×105, the remaining
spleen cells were used in cytotoxic killing assays carried out in
parallel as described below), were added into the coated wells of
an ELISPOT plate in the presence of medium alone (as negative
controls), the HIV peptide pool (50 ng/ml per peptide), the HIV
CLP97 peptide (10 µg/ml) or the negative control influenza
HA2 peptide (10 µg/ml). ConA at 5 µg/ml (Sigma-Aldrich Inc.)
was used as a positive control. The plates were incubated at
37 °C for 20 h, washed with PBS containing 0.05% Tween 20,
then incubated with biotinylated detection Ab followed by
enzyme conjugate streptavidin-HRP. The plates were finally
developed using an AEC substrate kit according to the
manufacture's instruction (Sigma-Aldrich Inc.). Spot-forming
cells (SFC) were imaged and enumerated using an ELISPOT
plate reader (Cellular Technology Ltd., Cleveland, OH). Cells
stimulated with medium alone were used as background con-
trols. Cells stimulated with the irrelevant peptide HA2 were
used as negative controls for Ag specificity. HIV-specific T cell
responses (SFC/106 spleen cells) were calculated by subtracting
the background (medium-stimulated wells) from the peptide-
stimulated wells.
Cytotoxic killing assay
Cytotoxic activity of the spleen cells from immunized mice
was determined by a flow cytometry-based killing assay that
detects cleaved caspase 3 in target cells (He et al., 2005). Spleen
cells from the sacrificed mice were cultured with medium alone
(as negative controls) or with the HIV envelope peptides at
37 °C for seven days. These in vitro-re-stimulated spleen cells
were used as effector cells. Mouse mast cells p815 (H-2d) were
maintained in RPMI 1640 supplemented with 10% FBS and
used as target cells. Briefly, p815 cells were labeled with a cell
tracker dye DDAO-SE (Invitrogen) at 0.4 µM in PBS for 15 min
at 37 °C then pulsed with HIVenvelope peptides (200 ng/ml for
each peptide) for 1 h at 37 °C. Then 2×105 peptide-loaded,
DDAO-SE-labeled p815 cells were mixed with 1×106 re-
stimulated spleen cells (effector:target ratio 5:1) and incubated
at 37 °C for 3 h. The cells were then washed with PBS-10%
FBS and permeabilized using BD Cytofix/Cytoperm kit (BD
Biosciences) at room temperature for 15 min. After washing
twice, the cells were stained with PE-conjugated rabbit Abspecific for the activated form of caspase 3 (BD Biosciences) for
1 h in the dark and subsequently fixed in 1% paraformaldehyde.
Samples were analyzed using FACSCalibur flow cytometer
(BD Biosciences) by collecting 200,000 events per sample, and
data analysis was performed using FlowJo software, Version
7.1.3 (Tree Star Inc., Ashland, OR).
Phenotyping of HIV-specific CD8+ memory T cells
Mice were sacrificed four weeks after the ALVAC boost in
order to analyze the HIV-gp140 specific CD8+ memory T cell
response. Draining popliteal lymph nodes were removed and
disaggregated, and cells were washed with PBS containing 2%
FBS and incubated with 10 µg/ml of PE-conjugated H-2Dd/
CLP97 tetrameric complex (purchased from the tetramer core
facility of Canadian Network for Vaccine and Immunother-
apeutics, Quebec, Canada) for 15 min at 37 °C. Cells were
subsequently labeled with PerCP-Cy5.5-conjugated anti-CD8,
APC-conjugated anti-CD44 and FITC-conjugated anti-CD62 L
monoclonal Abs (BD Biosciences) for 30 min on ice. Labeled
cells were washed twice in PBS-2% FBS, fixed in 1%
paraformaldehyde and analyzed by flow cytometry.
Statistic analysis
The statistical significance (pb0.05) of the differences in the
cells transfected with different DNA constructs, and in the
immune responses among the immunization groups was deter-
mined by ANOVA analysis followed by Fisher's LSD protected
t-test for multiple comparisons, using GB-STAT software
Version 7.0 (Dynamic Microsystems Inc., Silver Spring, MD).
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